Galectin-3 expression in donor T cells reduces GvHD severity and lethality after allogeneic hematopoietic cell transplantation

Cell Rep. 2023 Mar 28;42(3):112250. doi: 10.1016/j.celrep.2023.112250. Epub 2023 Mar 15.

Abstract

Abundant donor cytotoxic T cells that attack normal host organs remain a major problem for patients receiving allogeneic hematopoietic cell transplantation (allo-HCT). Despite an increase in our knowledge of the pathobiology of acute graft versus host disease (aGvHD), the mechanisms regulating the proliferation and function of donor T cells remain unclear. Here, we show that activated donor T cells express galectin-3 (Gal-3) after allo-HCT. In both major and minor histocompatibility-mismatched models of murine aGvHD, expression of Gal-3 is associated with decreased T cell activation and suppression of the secretion of effector cytokines, including IFN-γ and GM-CSF. Mechanistically, Gal-3 results in activation of NFAT signaling, which can induce T cell exhaustion. Gal-3 overexpression in human T cells prevents severe disease by suppressing cytotoxic T cells in xenogeneic aGvHD models. Together, these data identify the Gal-3-dependent regulatory pathway in donor T cells as a critical component of inflammation in aGvHD.

Keywords: CP: Immunology; GI biopsies; NFAT; T cells; allogeneic hematopoietic cell transplantation; galectin-3; graft versus host disease; retroviral transduction.

Publication types

  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Galectin 3 / genetics
  • Graft vs Host Disease* / metabolism
  • Hematopoietic Stem Cell Transplantation* / methods
  • Humans
  • Mice
  • T-Lymphocytes*
  • Transplantation, Homologous

Substances

  • Galectin 3